1. Home
  2. ATNM vs JMM Comparison

ATNM vs JMM Comparison

Compare ATNM & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.13

Market Cap

45.2M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Multi-Market Income Fund (MA)

JMM

Nuveen Multi-Market Income Fund (MA)

HOLD

Current Price

$6.20

Market Cap

58.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
JMM
Founded
2000
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
45.2M
58.5M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
JMM
Price
$1.13
$6.20
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
113.7K
3.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
5.44%
EPS Growth
30.60
N/A
EPS
N/A
N/A
Revenue
$81,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$5.68
52 Week High
$1.95
$6.52

Technical Indicators

Market Signals
Indicator
ATNM
JMM
Relative Strength Index (RSI) 46.79 52.39
Support Level $1.02 $6.19
Resistance Level $1.71 $6.26
Average True Range (ATR) 0.08 0.05
MACD 0.02 0.00
Stochastic Oscillator 63.00 33.33

Price Performance

Historical Comparison
ATNM
JMM

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

Share on Social Networks: